JPRN-jRCT2071230094已完成Unknown
Trastuzumab BS 60mg,150mg NK for intravenous infusion. Long-term specific use results survey targeting gastric cancer patients with confirmed HER2 overexpression. - /
/ / /0 个研究点目标入组 150 人开始时间: 2023年11月22日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •HER2 positive gastric cancer
排除标准
- •Not set: The following is set as a precaution when selecting patients.
研究者
相似试验
已完成
不适用
Safety and Efficacy of Trastuzumab BSGastric CancerNCT04181333Pfizer8
已完成
不适用
Feasibility study of a short Trastuzumab infusion in patients with breast cancer.breast cancerJPRN-UMIN000018294IPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITA20
已完成
2 期
Phase II trial of Trastuzumab in combination with Abraxane for patients with HER2-positive metastatic breast cancerHER2-positive Metastatic breast cancerJPRN-UMIN000006159Kumamoto Breast Cancer Cooperative Group23
已完成
2 期
The effect of anti-HER2 therapy in metastatic breast cancer wih HER2-negative primary tumor but HER2-positive circulating tumor cells10006232<p>Breast cancer, borstkanker, HER2, ER, PIK3CA, CTC, circulating tumor cell, circulerende tumorcellen, metastasen, metastasis, trastuzumab, herceptin, docetaxel</p>NL-OMON20549Erasmus MC Cancer Institute, department of Medical Oncology18
进行中（未招募）
不适用
Single Intravenous Administration of TB-402 for the Prophylaxis of Venous hromboembolic Events (VTE) After Total Knee Replacement Surgery: A Dose-Escalating, Multicenter, Randomised, Active-Controlled Open Label StudyMedDRA version: 9.1Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisVenous thrombolic eventsEUCTR2008-004539-39-LVThromboGenics N.V300